Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 2, 2010

PolyTherics and Zealand Ink PEGylated Peptide Therapeutics Collaboration

  • PolyTherics and Zealand Pharma entered a research collaboration focused on the development of PEGylated forms of peptide-based therapeutics against metabolic, cardiovascular, and gastrointestinal diseases.

    The partnership will apply PolyTherics’ PEGylation technologies to specific peptide candidates discovered by Zealand. Funding will come from the EUREKA Eurostars Program, which provides support to SMEs.

    The companies say their collaboration is expected to run for 24 months. During the first year they will carry out experimental research, and over the second 12 months they aim to select lead candidates for preclinical development.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »